Form 4: Exelixis EVP Amy C. Peterson Reports Stock Transactions

EVP Amy C. Peterson reports acquisition and disposal of Exelixis stock, including shares withheld for taxes and sales on the open market.

Summary

• On May 15, 2025, Amy C. Peterson, EVP of Product Development & Medical Affairs and CMO at Exelixis, had 8,303 shares withheld to cover taxes related to vesting restricted stock units at a price of $44.65.
• On May 16, 2025, Peterson exercised options to acquire 40,000 shares at $21.75 per share.
• Also on May 16, 2025, Peterson sold 72,776 shares at an average price of $45.47.
• Following these transactions, Peterson beneficially owns 465,393 shares of Exelixis common stock.
• This includes 453,166 shares that will be issued upon the vesting of RSUs and PSUs.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of stock transactions, with no inherent positive or negative implications for the company's performance.

Industry Context

This filing is a routine disclosure of stock transactions by a company executive, which is common in the pharmaceutical industry. It provides transparency into the executive's holdings and trading activities.

Comparison to Industry Standards

• Executive stock transactions are a common occurrence in publicly traded companies, including pharmaceutical firms like Exelixis.
• Similar filings are regularly made by executives at companies like Pfizer, Amgen, and Gilead Sciences.
• The size and frequency of these transactions can vary based on individual compensation structures and company performance.

Stakeholder Impact

• Shareholders may be interested in executive stock transactions as an indicator of management's confidence in the company.
• The transactions themselves are unlikely to have a significant impact on the company's operations or financial performance.

Key Dates

Keywords

Form 4, Beneficial Ownership, Stock Transactions, Exelixis, Peterson, Equity Securities